Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab + lenvatinib neoadjuvant study in potentially resectable hepatocellular carcinoma
ChiCTR2300069478Phase 2Not yet recruiting
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Mar 2023
- Modality
- Small Molecules, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of envafolimab and lenvatinib in hepatocellular carcinoma (HCC), sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoint: Pathologic complete response rate. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
envafolimablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2300069478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069478.